{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:51:39Z","timestamp":1780645899606,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"4","content-domain":{"domain":["ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.ejim.2012.11.007","type":"journal-article","created":{"date-parts":[[2012,12,11]],"date-time":"2012-12-11T20:16:22Z","timestamp":1355256982000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Evolving strategies for the use of spironolactone in cardiovascular disease"],"prefix":"10.1016","volume":"24","author":[{"given":"Oscar M.P.","family":"Jolobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2012.11.007_bb0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.2.5195.339","article-title":"Use of spironolactone and hydrochrothiazide in treatment of oedema","volume":"2","author":"Farrelly","year":"1960","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2012.11.007_bb0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.11.007_bb0350","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.11.007_bb0355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.11.007_bb0360","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10741-005-2351-3","article-title":"Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure","volume":"10","author":"Zannad","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2012.11.007_bb0035","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin\u2013angiotensin\u2013aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.11.007_bb0040","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/01.CIR.104.3.286","article-title":"Usefulness of serum carboxy-terminal propeptide of procollagen Type 1 in assessment of cardioprotective ability of antihypertensive treatment in hypertensive patients","volume":"104","author":"Lopez","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.11.007_bb0045","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1097\/HJH.0b013e32833d0177","article-title":"Increased levels of oxidative stress, subclinical inflammation, and myocardial fibrosis markers in primary aldosteronism patients","volume":"28","author":"Stehr","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2012.11.007_bb0050","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1097\/HJH.0b013e3283550f93","article-title":"Adrenalectomy reverses myocardial fibrosis in patients with primary aldosteronism","volume":"30","author":"Lin","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2012.11.007_bb0055","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodelling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.11.007_bb0060","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1136\/hrt.2005.080150","article-title":"Characteristics of left ventricular diastolic dysfunction in the community: an echocardiographic survey","volume":"92","author":"Abhayaratna","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ejim.2012.11.007_bb0065","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.amjcard.2004.11.006","article-title":"Contribution of left ventricular diastolic dysfunction to heart failure regardless of ejection fraction","volume":"95","author":"Brucks","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0070","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.amjcard.2005.03.055","article-title":"Usefulness of tissue Doppler and Color M-mode indexes of left ventricular diastolic function in predicting outcomes in systolic left ventricular heart failure (From ADEPT Study)","volume":"96","author":"Troughton","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0075","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.cardfail.2011.04.007","article-title":"Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction Trial (RAAM-OEF)","volume":"17","author":"Deswal","year":"2011","journal-title":"J Card Fail"},{"key":"10.1016\/j.ejim.2012.11.007_bb0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/eurjhf\/hfq087","volume":"12","author":"Edelman","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2012.11.007_bb0085","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2012.11.007_bb0090","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1161\/HYPERTENSIONAHA.111.186072","article-title":"Left ventricular failure produces profound lung remodelling and pulmonary hypertension in mice. Heart failure causes severe lung disease","volume":"59","author":"Chen","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2012.11.007_bb0095","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction a community study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0365","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4065\/84.2.191","article-title":"Pulmonary hypertension: diagnosis and management","volume":"84","author":"McGoon","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2012.11.007_bb0105","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1161\/CIRCULATIONAHA.112.094722","article-title":"Aldosterone inactivates the endothelin-B receptor via a cysteinyl thiol redox switch to decrease pulmonary endothelial nitric oxide levels and modulate pulmonary arterial hypertension","volume":"126","author":"Maron","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.11.007_bb0110","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/sj.bjp.0701785","article-title":"Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat","volume":"123","author":"McCulloch","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0115","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0002-9149(02)02451-7","article-title":"Usefulness of endothelin-1 concentration in capillary blood in patients with mitral stenosis as a predictor of regression of pulmonary hypertension after mitral valve replacement or valvuloplasty","volume":"90","author":"Snopek","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0370","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0002-9149(99)00643-8","article-title":"Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis","volume":"85","author":"Faggiano","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0375","first-page":"74","article-title":"Humoral profile of patients with severe aortic stenosis[article in Czech; abstract in English; data presented using international nomenclature]","volume":"139","author":"Hrudova","year":"2000","journal-title":"Cas Lek Cesk"},{"key":"10.1016\/j.ejim.2012.11.007_bb0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2261-11-72","article-title":"Role of aldosterone on lung structural remodelling and right ventricular function in congestive heart failure","volume":"11","author":"Chabot","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2012.11.007_bb0135","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"10.1016\/j.ejim.2012.11.007_bb0380","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1097\/00005344-200110001-00017","article-title":"Comparison of neurohormonal effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure","volume":"38","author":"Tsutsui","year":"2001","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0145","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/0735-1097(95)00332-0","article-title":"Adverse consequences of high sympathetic nervous activity in the failing human heart","volume":"26","author":"Kaye","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0150","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10571-005-4011-5","article-title":"Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities","volume":"25","author":"Saavedra","year":"2005","journal-title":"Cell Mol Neurobiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0155","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/clpt.2009.117","article-title":"Pharmacological treatment of heart failure\u2014a view from the brain","volume":"86","author":"Felder","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejim.2012.11.007_bb0160","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tem.2011.02.001","article-title":"Mineralocorticoid receptors in the brain and cardiovascular regulation: minority rule?","volume":"22","author":"Gomez-Sanchez","year":"2011","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.ejim.2012.11.007_bb0165","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1751-7133.2011.00252.x","article-title":"Association of furosemide dose with clinical status, left ventricular dysfunction, natriuretic peptides, and outcome in clinically stable patients with chronic systolic heart failure","volume":"18","author":"Dini","year":"2012","journal-title":"Congest Heart Fail"},{"key":"10.1016\/j.ejim.2012.11.007_bb0385","article-title":"Cardiorenal syndrome Type 1. Pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure","author":"Ronoco","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0175","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1681\/ASN.2010040384","article-title":"Angiotensin II as a morphogenetic cytokine stimulating renal fibrogenesis","volume":"22","author":"Ruster","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0390","series-title":"Neural control of renal function Chapter 5","article-title":"Neural control of renin secretion rate","author":"Kopp","year":"2011"},{"key":"10.1016\/j.ejim.2012.11.007_bb0395","doi-asserted-by":"crossref","first-page":"F1178","DOI":"10.1152\/ajprenal.00532.2009","article-title":"Direct fibrogenic effects of aldosterone on normotensive kidney: an effect modified by 11 B-HSD activity","volume":"298","author":"Brem","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0190","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1038\/sj.ki.5002564","article-title":"Thiazide-induced subtle renal injury not observed in states of equivalent hypokalemia","volume":"72","author":"Reungjui","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2012.11.007_bb0195","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2011.03.029","article-title":"Aldosterone-induced fibrosis in the kidney: questions and controversies","volume":"58","author":"Brem","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2012.11.007_bb0200","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IJGM.S16635","article-title":"Diuretics as pathogenetic treatment for heart failure","volume":"4","author":"Guglin","year":"2011","journal-title":"Int J Gen Med"},{"key":"10.1016\/j.ejim.2012.11.007_bb0205","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.amjcard.2011.10.027","article-title":"Frequency and predictors of hyperkalemia in patients >60years of age with heart failure undergoing intense medical therapy","volume":"109","author":"Muzzarelli","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0210","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ahj.2011.12.003","article-title":"Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy","volume":"163","author":"Maeder","year":"2012","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2012.11.007_bb0400","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1445-5994.1986.tb01119.x","article-title":"Combined spironolactone and converting enzyme inhibitor therapy for refractory heart failure","volume":"16","author":"Ikram","year":"1986","journal-title":"Aust N Z J Med"},{"key":"10.1016\/j.ejim.2012.11.007_bb0405","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction. Insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.11.007_bb0225","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin\u2013angiotensin\u2013aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.11.007_bb0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","article-title":"Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases","volume":"327","author":"Wrenger","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejim.2012.11.007_bb0410","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","article-title":"Eplerenone is not superior to older and less expensive aldosterone antagonists","volume":"125","author":"Chatterjee","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2012.11.007_bb0240","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.ejheart.2008.09.014","article-title":"Direct pro-arrhythmic effects of angiotensin II can be suppressed by AT1 receptor blockade in human atrial myocardium","volume":"10","author":"Von Lewinski","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2012.11.007_bb0245","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2009.09.045","article-title":"Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation","volume":"55","author":"Tsai","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0250","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000210398","article-title":"Decreased connexion 43 and increased fibrosis in atrial regions susceptible to complex fractionated atrial electrograms","volume":"114","author":"Liu","year":"2009","journal-title":"Cardiology"},{"key":"10.1016\/j.ejim.2012.11.007_bb0415","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jacc.2008.03.045","article-title":"Extracellular matrix alterations in patients with paroxysmal and persistent atrial fibrillation","volume":"52","author":"Kallergis","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0260","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2012.11.007_bb0265","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2007.09.026","article-title":"Structural and functional remodelling of the left atrium","volume":"51","author":"Casaclang-Verzosa","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0420","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1159\/000106680","article-title":"Evolution of left atrial systolic and diastolic functions in different stages of hypertension: distinct effects of blood pressure control","volume":"109","author":"Tsai","year":"2008","journal-title":"Cardiology"},{"key":"10.1016\/j.ejim.2012.11.007_bb0280","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1016\/S0735-1097(02)02373-2","article-title":"Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women","volume":"40","author":"Tsang","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0285","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jash.2010.10.001","article-title":"The effect of low-dose spironolactone on resistant hypertension","volume":"4","author":"Engbaek","year":"2010","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ejim.2012.11.007_bb0290","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin\u2013angiotensin system blockade in resistant hypertension: a prospective, randomised, open blinded end point study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2012.11.007_bb0295","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/HYPERTENSIONAHA.108.123455","article-title":"A simplified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial","volume":"53","author":"Feldman","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2012.11.007_bb0425","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.0954-6820.1980.tb09718.x","article-title":"Body fluid volumes and the response of renin and aldosterone to short- and long-term thiazide therapy of essential hypertension","volume":"207","author":"Van Brummelen","year":"1980","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.ejim.2012.11.007_bb0305","doi-asserted-by":"crossref","first-page":"43S","DOI":"10.1111\/j.1365-2125.1987.tb03121.x","article-title":"Captopril and hydrochlorothiazide: rationale for their combination","volume":"23","author":"Ambrosioni","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0310","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2008-2660","article-title":"Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients","volume":"94","author":"Menon","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2012.11.007_bb0315","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/HYPERTENSIONAHA.112.194787","article-title":"Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients","volume":"60","author":"Raheja","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2012.11.007_bb0320","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1161\/CIRCULATIONAHA.106.668863","article-title":"Relationship between central sympathetic drive and magnetic resonance imaging-determined left ventricular mass in essential hypertension","volume":"115","author":"Burns","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2012.11.007_bb0325","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/HJH.0b013e328332fa44","article-title":"Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy)","volume":"28","author":"Rieck","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2012.11.007_bb0330","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1210\/jc.2010-0823","article-title":"Reversible sympathetic activity in hypertensive patients with primary aldosteronism","volume":"95","author":"Kontak","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2012.11.007_bb0430","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jacc.2012.05.036","article-title":"A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension","volume":"60","author":"Pokushalov","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0435","unstructured":"Greve AM, Gerdts E, Boman K, Gohlke-Baerwolf C, Rossebo AB, Nieanaber CA et al. Prognostic importance of atrial fibrillation in asymptomatic aortic stenosis: the Simvastatin and Ezetimibe in Aortic Stenosis study. Int J Cardiol, 2011 (E Pub ahead of print), http:\/\/dx.doi.org\/10.1016\/j.jcard2011.09.064."},{"key":"10.1016\/j.ejim.2012.11.007_bb0345","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.mce.2011.05.005","article-title":"Central regulation of blood pressure by the mineralocorticoid receptor","volume":"350","author":"Gomez-Sanchez","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.ejim.2012.11.007_bb0440","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s11906-012-0297-0","article-title":"The ubiquitous mineralocorticoid receptor: clinical implications","volume":"14","author":"Hawkins","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.ejim.2012.11.007_bb9000","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512002944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512002944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T04:05:58Z","timestamp":1540008358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620512002944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":71,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0953620512002944"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2012.11.007","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolving strategies for the use of spironolactone in cardiovascular disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2012.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}